Case number 2016-2610
UCB, Inc. v. Accord Healthcare, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | UCB, INC. v. ACCORD HEALTHCARE, INC. [OPINION] [precedential] (0) |
| Feb 19, 2019 | 154 | The petition for writ of certiorari, [18-692], filed on 11/21/2018, was Denied on 02/19/2019. [587462] [JAB] [Entered: 02/20/2019 01:42 PM] (1) |
| Nov 27, 2018 | 153 | Petition for writ of Certiorari filed on 11/21/2018, and placed on the docket 11/27/2018, in the Supreme Court of the United States. Supreme Court #: 18-692, Mylan Pharmaceuticals Inc., et al v. UCB, Inc., et al. [568463] [JAB] [Entered: 11/29/2018 10:22 AM] (1) |
| Nov 19, 2018 | 152 | The petition for writ of certiorari, [18-441], filed on 10/03/2018, was Denied on 11/19/2018. [566614] [JAB] [Entered: 11/20/2018 10:01 AM] (1) |
| Oct 9, 2018 | 151 | Petition for writ of Certiorari filed on 10/03/2018, and placed on the docket 10/09/2018, in the Supreme Court of the United States. Supreme Court #: 18-441, Accord Healthcare, Inc., et al. v. UCB, Inc., et al. [556231] [JAB] [Entered: 10/11/2018 08:22 AM] (1) |
| Aug 31, 2018 | 150 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [546655] [16-2610, 16-2683, 16-2685, 16-2698, 16-2710, 17-1001] [SJ] [Entered: 08/31/2018 11:13 AM] (1) |
| Aug 24, 2018 | 147 | ORDER filed denying [145] petition for en banc rehearing filed by Mylan Pharmaceuticals Inc., Mylan Inc., Sun Pharmaceutical Industries, Ltd., Sun Pharma Global FZE, Alembic Pharmaceuticals Ltd., Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited, denying [132] petition for en banc rehearing filed by Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [545231] [SJ] [Entered: 08/24/2018 11:35 AM] (3) |
| Aug 24, 2018 | 148 | MOTION of Appellants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc. to withdraw counsel Samuel S. Park [Consent: unopposed]. Service: 08/24/2018 by email. [545240] [16-2610] [Charles Klein] [Entered: 08/24/2018 11:54 AM] (8) |
| Aug 24, 2018 | 149 | **TEXT ONLY** ORDER granting motion to withdraw attorney [148] Samuel Park filed by Appellants Breckenridge Pharmaceutical, Inc., Sun Pharmaceutical Industries, Ltd., Watson Pharma, Inc., Aurobindo Pharma Ltd., Watson Laboratories, Inc. - Florida, Sun Pharma Global FZE, Amneal Pharmaceuticals of New York, LLC, MSN Laboratories Pvt. Ltd., Amneal Pharmaceuticals LLC and Aurobindo Pharma USA, Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [545307] [SJ] [Entered: 08/24/2018 01:49 PM] (0) |
| Jul 25, 2018 | 146 | 18 paper copies of the petition for en banc rehearing [145] received from Appellants Alembic Pharmaceuticals Ltd., Cadila Healthcare Limited, Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd. and Zydus Pharmaceuticals (USA) Inc. [538505] [JAB] [Entered: 07/25/2018 01:04 PM] (0) |
| Jul 23, 2018 | 142 | 18 paper copies of the petition for en banc rehearing [132] received from Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. [537552] [SJ] [Entered: 07/23/2018 08:34 AM] (0) |
| Jul 23, 2018 | 143 | Entry of appearance for Tasha Thomas as of counsel for Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 07/23/2018 by email. [537855] [16-2610] [Tasha Thomas] [Entered: 07/23/2018 03:17 PM] (2) |
| Jul 23, 2018 | 144 | Amended Certificate of Interest for the Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 07/23/2018 by email. [538005] [16-2610] [Nicole Stafford] [Entered: 07/23/2018 08:54 PM] (4) |
| Jul 23, 2018 | 145 | Petition for en banc rehearing filed by Appellants Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc. and Alembic Pharmaceuticals Ltd.. Service: 07/23/2018 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 07/25/2018 [538006] [16-2610] [Nicole Stafford] [Entered: 07/23/2018 09:22 PM] (77) |
| Jul 20, 2018 | 139 | MOTION of Appellant Alembic Pharmaceuticals Ltd. to withdraw counsel Jeffer Ali [Consent: unopposed]. Service: 07/20/2018 by email. [537214] [16-2610] [Todd Werner] [Entered: 07/20/2018 11:00 AM] (5) |
| Jul 20, 2018 | 140 | **TEXT ONLY** ORDER granting motion to withdraw attorney [139] M. Jeffer Ali filed by Appellant Alembic Pharmaceuticals Ltd.. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [537257] [SJ] [Entered: 07/20/2018 11:54 AM] (0) |
| Jul 20, 2018 | 141 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [134], ERROR: law firm listed does not match attorney's filing credentials. CORRECTION: please update attorney's ECF account. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [537280] [SJ] [Entered: 07/20/2018 12:03 PM] (0) |
| Jul 19, 2018 | 132 | Petition for en banc rehearing filed by Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 07/19/2018 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 07/23/2018 [537054] [16-2610] [Richard Greco] [Entered: 07/19/2018 02:39 PM] (68) |
| Jul 19, 2018 | 133 | Entry of appearance for Todd S. Werner as principal counsel for Appellant Alembic Pharmaceuticals Ltd.. Service: 07/19/2018 by email. [537109] [16-2610] [Todd Werner] [Entered: 07/19/2018 04:05 PM] (2) |
| Jul 19, 2018 | 134 | Amended Entry of appearance for James Trainor as of counsel for Appellees UCB, Inc., UCB BioPharma SPRL, Research Corporation Technologies, Inc. and Harris FRC Corporation. Service: 07/19/2018 by email. [537110] [16-2610] [James Trainor] [Entered: 07/19/2018 04:06 PM] (2) |
| Jul 19, 2018 | 135 | Amended Entry of appearance for Adam R. Gahtan as principal counsel for Appellees UCB, Inc., UCB BioPharma SPRL, Research Corporation Technologies, Inc. and Harris FRC Corporation. Service: 07/19/2018 by email. [537112] [16-2610] [Adam Gahtan] [Entered: 07/19/2018 04:10 PM] (2) |
| Jul 19, 2018 | 136 | Amended Entry of appearance for Laura T. Moran as of counsel for Appellees UCB, Inc., UCB BioPharma SPRL, Research Corporation Technologies, Inc. and Harris FRC Corporation. Service: 07/19/2018 by email. [537113] [16-2610] [Laura Moran] [Entered: 07/19/2018 04:19 PM] (2) |
| Jul 19, 2018 | 137 | Amended Entry of appearance for Eric M. Majchrzak as of counsel for Appellees UCB, Inc., UCB BioPharma SPRL, Research Corporation Technologies, Inc. and Harris FRC Corporation. Service: 07/19/2018 by email. [537128] [16-2610] [Eric Majchrzak] [Entered: 07/19/2018 05:05 PM] (2) |
| Jul 19, 2018 | 138 | Certificate of Interest for the Appellant Alembic Pharmaceuticals Ltd.. Service: 07/19/2018 by email. [537130] [16-2610] [Todd Werner] [Entered: 07/19/2018 05:39 PM] (3) |
| Jun 13, 2018 | 131 | ORDER filed granting motion to extend time to file petition for rehearing/en banc [130] filed by Appellants Accord Healthcare, Inc., et al. Petition for Rehearing due on or before 07/23/2018. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [529193] [SJ] [Entered: 06/13/2018 04:12 PM] (2) |
| Jun 11, 2018 | 130 | MOTION of Appellants Mylan Inc., Mylan Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, Intas Pharmaceuticals Ltd., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc., Zydus Pharmaceuticals (USA) Inc. and Accord Healthcare, Inc. to extend the time to file a Combined Petition for Panel Rehearing and Rehearing En Banc until 07/23/2018 [Consent: unopposed]. Service: 06/11/2018 by email. [528573] [16-2610] [Nicole Stafford] [Entered: 06/11/2018 10:10 PM] (22) |
| May 23, 2018 | 129 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (Precedential Opinion). (For the Court: Prost, Chief Judge; Bryson, Circuit Judge and Stoll, Circuit Judge). Dissenting Opinion filed by Chief Judge Prost. [523840] [16-2610, 16-2683, 16-2685, 16-2698, 16-2710, 17-1001] [SJ] [Entered: 05/23/2018 09:52 AM] (44) |
| Mar 7, 2018 | 126 | MOTION of Appellants Mylan Inc. and Mylan Pharmaceuticals Inc. to withdraw counsel Eric C. Arnell. Any response is due within 10 days of service [Consent: unopposed]. Service: 03/07/2018 by email. [503179] [Nicole Stafford] [Entered: 03/07/2018 12:06 PM] (6) |
| Mar 7, 2018 | 127 | **TEXT ONLY** ORDER granting motion to withdraw attorney [126] Eric Arnell filed by Appellants Mylan Pharmaceuticals Inc. and Mylan Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [503230] [SJ] [Entered: 03/07/2018 01:36 PM] (0) |
| Mar 7, 2018 | 128 | CORRECTED ENTRY: RESPONSE of Appellants Accord Healthcare, Inc., Alembic Pharmaceuticals Ltd., Apotex Corp., Mylan Pharmaceuticals Inc. and Zydus Pharmaceuticals (USA) Inc. to the supplemental authority [125] filed by Appellees Research Corporation Technologies, Inc., UCB, Inc., UCB BioPharma SPRL and Harris FRC Corporation in 16-2610. Service: 03/07/2018 by email. [503247]--[Edited 03/07/2018 by SMJ - Reason: to correct event used] [Richard Greco] [Entered: 03/07/2018 02:07 PM] (2) |
| Feb 27, 2018 | 125 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Service: 02/27/2018 by email. [501267] [Adam Gahtan] [Entered: 02/27/2018 09:39 AM] (8) |
| Aug 8, 2017 | 124 | Submitted after ORAL ARGUMENT by Richard G. Greco for Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd., Maureen L. Rurka for Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Zydus Pharmaceuticals (USA) Inc. and Dimitrios T. Drivas for Research Corporation Technologies, Inc., UCB, Inc., UCB BioPharma SPRL and Harris FRC Corporation. Panel: Judge: Prost , Judge: Bryson , Judge: Stoll. [452059] [JAB] [Entered: 08/08/2017 10:45 AM] (0) |
| Jul 24, 2017 | 122 | Clerk's Note to the File: The court requires an additional 6 copies of the opening brief from Accord/Intas. The previously filed paper copies are missing pages 47-57, as well as the back cover. Paper copies due 7/26. (Ref: Opening Brief , [85]) [448662] [SJ] [Entered: 07/24/2017 12:53 PM] (0) |
| Jul 24, 2017 | 123 | 6 paper copies of the Corrected Opening Brief [85] received from Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd. [448804] [CW] [Entered: 07/24/2017 04:10 PM] (0) |
| Jul 18, 2017 | 120 | Notice to counsel for Appellant Intas Pharmaceuticals Ltd.: The record of this case indicates that the Response to Oral Argument Order has not been filed. The response was due on or before 07/17/2017. Counsel should promptly docket the Response to Oral Argument Order event and designate which attorney will present argument for the party. Service as of this date by Clerk of Court. [447370] [JAB] [Entered: 07/18/2017 12:55 PM] (0) |
| Jul 18, 2017 | 121 | CORRECTED Response to oral argument order from the Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. designating Richard G. Greco as arguing attorney. Designated time for argument: 4 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [447420] [Richard Greco] [Entered: 07/18/2017 02:34 PM] (0) |
| Jul 17, 2017 | 118 | Response to oral argument order from the Appellant Accord Healthcare, Inc.. designating Richard G. Greco as arguing attorney. Designated time for argument: 4 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [446977] [Richard Greco] [Entered: 07/17/2017 01:09 PM] (0) |
| Jul 17, 2017 | 119 | Response to oral argument order from the Appellants Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Zydus Pharmaceuticals (USA) Inc.. designating Maureen L. Rurka as arguing attorney. Designated time for argument: 9 minutes. Designated time for rebuttal: 2 minutes. Service of other counsel by Notice of Docket Activity from this entry. [446985] [Maureen Rurka] [Entered: 07/17/2017 01:15 PM] (0) |
| Jul 13, 2017 | 117 | Response to oral argument order from the Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. designating Dimitrios T. Drivas as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [446221] [Dimitrios Drivas] [Entered: 07/13/2017 12:45 PM] (0) |
| Jun 21, 2017 | 116 | NOTICE OF CALENDARING. Panel: 1708F. Case scheduled Aug 08, 2017 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 203. Response to oral argument order due: 07/17/2017. Arguing counsel is required to check-in at the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [441176] [JAB] [Entered: 06/21/2017 04:16 PM] (0) |
| Apr 5, 2017 | 115 | RESPONSE of Appellants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc. to the supplemental authority [114] filed by Appellees Research Corporation Technologies, Inc., UCB, Inc., UCB BioPharma SPRL and Harris FRC Corporation in 16-2610. Service: 04/05/2017 by email. [421873] [Maureen Rurka] [Entered: 04/05/2017 08:20 PM] (3) |
| Mar 31, 2017 | 114 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Service: 03/31/2017 by email. [420740] [Adam Gahtan] [Entered: 03/31/2017 03:59 PM] (58) |
| Mar 17, 2017 | 113 | Notice from Appellants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc. regarding conflicts with oral argument (unavailable during the July Court week, July 10-14). Service: 03/17/2017 by email. [416769] [Maureen Rurka] [Entered: 03/17/2017 06:57 PM] (2) |
| Mar 16, 2017 | 111 | Notice from Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc. regarding conflicts with oral argument (unavailable during the June session, June 5, 2017 through June 9, 2017). Service: 03/16/2017 by email. [416157] [Adam Gahtan] [Entered: 03/16/2017 12:20 PM] (2) |
| Mar 16, 2017 | 112 | Letter from Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd. regarding conflicts with oral argument. Service: 03/16/2017 by email. [416419] [Gurpreet Walia] [Entered: 03/16/2017 07:20 PM] (2) |
| Mar 14, 2017 | 110 | 6 paper copies of the Confidential Joint Appendix (Vol. I-II) [107] received from Appellants Accord Healthcare, Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., et al. [415356] [KW] [Entered: 03/14/2017 02:33 PM] (0) |
| Mar 10, 2017 | 109 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 03/17/2017. [414322] [SJ] [Entered: 03/10/2017 11:46 AM] (0) |
| Mar 8, 2017 | 104 | 6 paper copies of the Reply Brief [101] received from Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd. [413432] [KW] [Entered: 03/08/2017 01:45 PM] (0) |
| Mar 8, 2017 | 105 | TENDERED from Appellants Accord Healthcare, Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, Intas Pharmaceuticals Ltd., MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc., Zydus Pharmaceuticals (USA) Inc. and Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Title: JOINT APPENDIX. Service: 03/08/2017 by email. [413461] [Maureen Rurka] [Entered: 03/08/2017 02:28 PM] (1162) |
| Mar 8, 2017 | 106 | TENDERED from Appellants Accord Healthcare, Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, Intas Pharmaceuticals Ltd., MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc., Zydus Pharmaceuticals (USA) Inc. and Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Title: CONFIDENTIAL JOINT APPENDIX Service: 03/08/2017 by email. [413463] [Maureen Rurka] [Entered: 03/08/2017 02:31 PM] (0) |
| Mar 8, 2017 | 107 | CONFIDENTIAL JOINT APPENDIX FILED (2 vols.) for Accord Healthcare, Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, Intas Pharmaceuticals Ltd., MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Zydus Pharmaceuticals (USA) Inc. [106]. Number of Pages: 1224. Service: 03/08/2017 by email. The paper copies of the brief should be received by the court on or before 03/17/2017. [414319] [SJ] [Entered: 03/10/2017 11:40 AM] (0) |
| Mar 8, 2017 | 108 | APPENDIX FILED (2 vols.) for Accord Healthcare, Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, Intas Pharmaceuticals Ltd., MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Zydus Pharmaceuticals (USA) Inc. [105]. Number of Pages: 1153. Service: 03/08/2017 by email. [414320] [SJ] [Entered: 03/10/2017 11:45 AM] (1162) |
| Mar 7, 2017 | 103 | 6 paper copies of the Reply Brief [102] received from Appellants Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, et al. [413043] [KW] [Entered: 03/07/2017 01:58 PM] (0) |
| Mar 1, 2017 | 100 | TENDERED from Appellants Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Zydus Pharmaceuticals (USA) Inc.. Title: REPLY BRIEF. Service: 03/01/2017 by email. [411787] [Maureen Rurka] [Entered: 03/01/2017 05:53 PM] (52) |
| Mar 1, 2017 | 102 | REPLY BRIEF FILED for Appellants Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Zydus Pharmaceuticals (USA) Inc. [100]. Number of Pages: 30. Service: 03/01/2017 by email. The paper copies of the brief should be received by the court on or before 03/14/2017. Appendix is due 03/08/2017. [412946] [SJ] [Entered: 03/07/2017 10:22 AM] (52) |
| Feb 28, 2017 | 99 | TENDERED from Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Title: REPLY BRIEF. Service: 02/28/2017 by email. [411065] [Richard Greco] [Entered: 02/28/2017 09:30 AM] (24) |
| Feb 28, 2017 | 101 | REPLY BRIEF FILED for Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd. [99]. Number of Pages: 17. Service: 02/28/2017 by email. The paper copies of the brief should be received by the court on or before 03/14/2017. [412942] [SJ] [Entered: 03/07/2017 10:12 AM] (24) |
| Feb 24, 2017 | 98 | Entry of appearance for Joshua Kushner as of counsel for Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 02/24/2017 by email. [410498] [Joshua Kushner] [Entered: 02/24/2017 02:43 PM] (2) |
| Feb 3, 2017 | 97 | 6 paper copies of the Response Brief [96] received from Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc. [404631] [KW] [Entered: 02/03/2017 02:43 PM] (0) |
| Feb 1, 2017 | 95 | TENDERED from Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Title: RESPONSE BRIEF. Service: 02/01/2017 by email. [403871] [Adam Gahtan] [Entered: 02/01/2017 03:19 PM] (80) |
| Feb 1, 2017 | 96 | BRIEF FILED for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc. [95]. Number of Pages: 65. Service: 02/01/2017 by email. The paper copies of the brief should be received by the court on or before 02/08/2017. [403961] [JB] [Entered: 02/01/2017 04:25 PM] (80) |
| Jan 27, 2017 | 93 | Entry of appearance for Christopher J. Glancy as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Service: 01/27/2017 by email. [402767] [Adam Gahtan] [Entered: 01/27/2017 04:08 PM] (4) |
| Jan 27, 2017 | 94 | Entry of appearance for Eric M. Majchrzak as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Service: 01/27/2017 by email. [402769] [Adam Gahtan] [Entered: 01/27/2017 04:11 PM] (4) |
| Dec 16, 2016 | 92 | Entry of appearance for David Steuer as of counsel for Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 12/16/2016 by email. [392008] [David Steuer] [Entered: 12/16/2016 06:05 PM] (2) |
| Dec 15, 2016 | 91 | ORDER filed. The motion [90] is granted. The appellees' response brief is due February 1, 2017 and the appellants' reply brief(s) due March 1, 2017. Service: 12/15/2016 by clerk. [391193] [LMS] [Entered: 12/15/2016 08:46 AM] (2) |
| Dec 13, 2016 | 90 | MOTION of Appellants Accord Healthcare, Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, Intas Pharmaceuticals Ltd., MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc., Zydus Pharmaceuticals (USA) Inc. and Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc. to extend the time to 02/01/2017 to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service, to extend the time to 03/01/2017 to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 12/13/2016 by email. [390762] [Adam Gahtan] [Entered: 12/13/2016 05:38 PM] (23) |
| Dec 5, 2016 | 89 | 6 paper copies of the Opening Brief [88] received from Appellants Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Zydus Pharmaceuticals (USA) Inc. [388615] [KW] [Entered: 12/06/2016 01:36 PM] (0) |
| Dec 2, 2016 | 86 | 6 paper copies of the Opening Brief [85] received from Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd. [387909] [KW] [Entered: 12/02/2016 02:27 PM] (0) |
| Dec 2, 2016 | 87 | TENDERED from Appellants Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Zydus Pharmaceuticals (USA) Inc.. Title: OPENING BRIEF. Service: 12/02/2016 by email. [388025] [Maureen Rurka] [Entered: 12/02/2016 06:31 PM] (219) |
| Dec 2, 2016 | 88 | BRIEF FILED for Appellants Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, MSN Laboratories Pvt. Ltd., Mylan Inc., Mylan Pharmaceuticals Inc., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Zydus Pharmaceuticals (USA) Inc. [87]. Number of Pages: 61. Service: 12/02/2016 by email. The paper copies of the brief should be received by the court on or before 12/12/2016. Appellees' brief is due 01/11/2017. [388137] [AT] [Entered: 12/05/2016 11:40 AM] (219) |
| Nov 30, 2016 | 84 | TENDERED from Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Title: OPENING BRIEF. Service: 11/30/2016 by email. [387132] [Richard Greco] [Entered: 11/30/2016 12:03 PM] (200) |
| Nov 30, 2016 | 85 | BRIEF FILED for Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd. [84]. Number of Pages: 57. Service: 11/30/2016 by email. The paper copies of the brief should be received by the court on or before 12/06/2016. [387448] [AT] [Entered: 12/01/2016 11:39 AM] (200) |
| Nov 29, 2016 | 83 | Entry of appearance for Gurpreet Singh Walia as of counsel for Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 11/29/2016 by email, US mail. [386899] [Gurpreet Walia] [Entered: 11/29/2016 03:36 PM] (2) |
| Nov 28, 2016 | 81 | Entry of appearance for Aden Allen as of counsel for Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 11/28/2016 by email. [386456] [Aden Allen] [Entered: 11/28/2016 05:35 PM] (2) |
| Nov 28, 2016 | 82 | Entry of appearance for Adam Burrowbridge as of counsel for Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 11/28/2016 by email. [386461] [Adam Burrowbridge] [Entered: 11/28/2016 05:42 PM] (2) |
| Nov 23, 2016 | 80 | ORDER filed. The motion [79] is granted to the extent that the official caption is revised to reflect that Actavis is not a party to these appeals. Service: 11/23/2016 by clerk. [385774] [LMS] [Entered: 11/23/2016 10:51 AM] (3) |
| Nov 18, 2016 | 79 | MOTION of Appellants Watson Laboratories, Inc. - Florida, Watson Pharma, Inc. and Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc. to withdraw party, Actavis, Inc. , as a party to this appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 11/18/2016 by email, US mail. [384750] [Samuel Park] [Entered: 11/18/2016 06:34 PM] (4) |
| Oct 14, 2016 | 71 | Entry of appearance for Ian Scott as principal counsel for Appellants Apotex Corp. and Apotex Inc.. Service: 10/14/2016 by email, US mail. [374162] [Ian Scott] [Entered: 10/14/2016 10:37 AM] (1) |
| Oct 14, 2016 | 72 | Entry of appearance for Richard T. Ruzich as of counsel for Appellants Apotex Corp. and Apotex Inc.. Service: 10/14/2016 by email. [374170] [Ian Scott] [Entered: 10/14/2016 10:39 AM] (1) |
| Oct 14, 2016 | 73 | Entry of appearance for Stephen R. Auten as of counsel for Appellants Apotex Corp. and Apotex Inc.. Service: 10/14/2016 by email. [374172] [Ian Scott] [Entered: 10/14/2016 10:41 AM] (1) |
| Oct 14, 2016 | 74 | Certificate of Interest for the Appellants Apotex Corp. and Apotex Inc.. Service: 10/14/2016 by email, US mail. [374180] [Ian Scott] [Entered: 10/14/2016 10:46 AM] (1) |
| Oct 14, 2016 | 75 | Docketing Statement for the Appellants Apotex Corp. and Apotex Inc.. Service: 10/14/2016 by email, US mail. [374184] [Ian Scott] [Entered: 10/14/2016 10:48 AM] (3) |
| Oct 14, 2016 | 76 | Transcript Purchase Order Form for the Appellants Apotex Corp. and Apotex Inc. indicating that a transcript is already on file. Service: 10/14/2016 by email, US mail. [374186] [Ian Scott] [Entered: 10/14/2016 10:49 AM] (1) |
| Oct 14, 2016 | 77 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [71], ERROR: The firm contact information on the entry of appearance does not correspond with what we have in our database. CORRECTION: Please update your firm name and contact information with the PACER service center. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [374276] [JB] [Entered: 10/14/2016 12:54 PM] (0) |
| Oct 14, 2016 | 78 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account of Mr. Ian Scott for Apotex Inc. and Apotex Corp. The e-mail address, (iscott@taft.law.com), associated with your CM/ECF account has generated a delivery failure notice. Counsel should promptly report a change in contact information with the Pacer Service Center (see Fed. Cir. R. 47.3(c)(1). [374485] [IW] [Entered: 10/14/2016 04:09 PM] (0) |
| Oct 11, 2016 | 67 | Entry of appearance for Jeffer Ali as principal counsel for Appellant Alembic Pharmaceuticals Ltd.. Service: 10/11/2016 by email. [373204] [M. Ali] [Entered: 10/11/2016 04:15 PM] (2) |
| Oct 11, 2016 | 68 | Entry of appearance for Sarah M. Stensland as of counsel for Appellant Alembic Pharmaceuticals Ltd.. Service: 10/11/2016 by email. [373205] [M. Ali] [Entered: 10/11/2016 04:16 PM] (2) |
| Oct 11, 2016 | 69 | Certificate of Interest for the Appellant Alembic Pharmaceuticals Ltd.. Service: 10/11/2016 by email. [373207] [M. Ali] [Entered: 10/11/2016 04:18 PM] (3) |
| Oct 11, 2016 | 70 | Docketing Statement for the Appellant Alembic Pharmaceuticals Ltd.. Service: 10/11/2016 by email. [373210] [M. Ali] [Entered: 10/11/2016 04:20 PM] (4) |
| Oct 7, 2016 | 59 | Entry of appearance for Samuel S. Park as of counsel for Appellants Actavis, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc.. Service: 10/07/2016 by email. [372846] [Samuel Park] [Entered: 10/07/2016 08:52 PM] (2) |
| Oct 7, 2016 | 60 | Entry of appearance for George C. Lombardi as principal counsel for Appellants Actavis, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc.. Service: 10/07/2016 by email. [372847] [Samuel Park] [Entered: 10/07/2016 08:54 PM] (2) |
| Oct 7, 2016 | 61 | Entry of appearance for Charles B. Klein as of counsel for Appellants Actavis, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc.. Service: 10/07/2016 by email. [372848] [Samuel Park] [Entered: 10/07/2016 08:56 PM] (2) |
| Oct 7, 2016 | 62 | Entry of appearance for Maureen L. Rurka as of counsel for Appellants Actavis, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc.. Service: 10/07/2016 by email. [372849] [Samuel Park] [Entered: 10/07/2016 08:57 PM] (2) |
| Oct 7, 2016 | 63 | Entry of appearance for John R. McNair as of counsel for Appellants Actavis, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc.. Service: 10/07/2016 by email. [372850] [Samuel Park] [Entered: 10/07/2016 08:58 PM] (2) |
| Oct 7, 2016 | 64 | Entry of appearance for Eimeric Reig-Plessis as of counsel for Appellants Actavis, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc.. Service: 10/07/2016 by email. [372851] [Samuel Park] [Entered: 10/07/2016 08:59 PM] (2) |
| Oct 7, 2016 | 65 | Certificate of Interest for the Appellants Actavis, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc.. Service: 10/07/2016 by email. [372852] [Samuel Park] [Entered: 10/07/2016 09:02 PM] (6) |
| Oct 7, 2016 | 66 | Docketing Statement for the Appellants Actavis, Inc., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc. - Florida and Watson Pharma, Inc.. Service: 10/07/2016 by email. [372853] [Samuel Park] [Entered: 10/07/2016 09:09 PM] (3) |
| Oct 6, 2016 | 55 | Entry of appearance for Nicole Stafford as principal counsel for Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 10/06/2016 by email. [372264] [Nicole Stafford] [Entered: 10/06/2016 01:36 PM] (2) |
| Oct 6, 2016 | 56 | Certificate of Interest for the Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 10/06/2016 by email. [372271] [Nicole Stafford] [Entered: 10/06/2016 01:43 PM] (2) |
| Oct 6, 2016 | 57 | Docketing Statement for the Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 10/06/2016 by email. [372272] [Nicole Stafford] [Entered: 10/06/2016 01:44 PM] (4) |
| Oct 6, 2016 | 58 | Entry of appearance for Eric Arnell as of counsel for Appellants Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 10/06/2016 by email. [372276] [Eric Arnell] [Entered: 10/06/2016 01:48 PM] (2) |
| Oct 5, 2016 | 48 | Entry of appearance for David B. Abramowitz as of counsel for Appellants Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc.. Service: 10/05/2016 by email, US mail. [371864] [David Abramowitz] [Entered: 10/05/2016 02:07 PM] (2) |
| Oct 5, 2016 | 49 | Docketing Statement for the Appellants Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc.. Service: 10/05/2016 by email, US mail. [371865] [David Abramowitz] [Entered: 10/05/2016 02:08 PM] (3) |
| Oct 5, 2016 | 50 | Certificate of Interest for the Appellants Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc.. Service: 10/05/2016 by email, US mail. [371866] [David Abramowitz] [Entered: 10/05/2016 02:09 PM] (2) |
| Oct 5, 2016 | 51 | Entry of appearance for Michael J. Gaertner as principal counsel for Appellants Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc.. Service: 10/05/2016 by email, US mail. [371932] [Michael Gaertner] [Entered: 10/05/2016 03:13 PM] (2) |
| Oct 5, 2016 | 52 | Entry of appearance for Timothy F. Peterson as of counsel for Appellants Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc.. Service: 10/05/2016 by email. [371936] [Timothy Peterson] [Entered: 10/05/2016 03:16 PM] (2) |
| Oct 5, 2016 | 53 | Entry of appearance for Andrea L. Wayda as of counsel for Appellants Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc.. Service: 10/05/2016 by email. [371958] [Andrea Wayda] [Entered: 10/05/2016 03:51 PM] (2) |
| Oct 5, 2016 | 54 | Entry of appearance for Hugh S. Balsam as of counsel for Appellants Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc.. Service: 10/05/2016 by email, US mail. [371997] [Hugh Balsam] [Entered: 10/05/2016 04:57 PM] (2) |
| Oct 3, 2016 | 45 | Note to file: LEAD APPEAL 2016-2610 is consolidated with appeal 2017-1001. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [370849] [AT] [Entered: 10/03/2016 11:53 AM] (0) |
| Oct 3, 2016 | 46 | Official caption revised to reflect the consolidation of the appeal filed by defendants Apotex Corp., Apotex Inc., docketed 10/3/16 as no. 2017-1001.. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [370853] [AT] [Entered: 10/03/2016 11:57 AM] (0) |
| Oct 3, 2016 | 47 | Clerk's Note to the File: Pursuant to the Fed. Cir. R. 31 practice note, the due date for all appellants' opening briefs is recalculated from the date of docketing of the later consolidated appeal (2017-1001, 10/3/16). Appellants' opening briefs are due 12/02/16. [370858] [AT] [Entered: 10/03/2016 12:02 PM] (0) |
| Sep 27, 2016 | 42 | Note to file: LEAD APPEAL 2016-2610 is consolidated with appeal 2016-2710. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [369509] [AT] [Entered: 09/27/2016 12:00 PM] (0) |
| Sep 27, 2016 | 43 | Official caption revised to reflect the consolidation of the appeal filed by defendant Alembic Pharmaceuticals Ltd., docketed 9/27/16 as 2016-2710. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [369518] [AT] [Entered: 09/27/2016 12:07 PM] (0) |
| Sep 27, 2016 | 44 | Clerk's Note to the File: Pursuant to the Fed. Cir. R. 31 practice note, the due date for all appellants' opening briefs is recalculated from the date of docketing of the later consolidated appeal (2016-2710, 9/27/16). Appellants' opening briefs are due 11/28/16. [369521] [AT] [Entered: 09/27/2016 12:10 PM] (0) |
| Sep 23, 2016 | 39 | Note to file: LEAD APPEAL 2016-2610 is consolidated with appeal 2016-2698. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [368896] [AT] [Entered: 09/23/2016 01:38 PM] (0) |
| Sep 23, 2016 | 40 | Official caption revised to reflect the consolidation of the appeal filed by defendants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Breckenridge Pharmaceutical, Inc., MSN Laboratories Pvt. Ltd., Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd., Watson Laboratories, Inc., – Florida nka Actavis Laboratories FL, Inc., Watson Pharma, Inc. nka Actavis Pharma, Inc., Actavis, Inc., docketed 9/23/16 as 2016-2698. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [368902] [AT] [Entered: 09/23/2016 01:49 PM] (0) |
| Sep 23, 2016 | 41 | Clerk's Note to the File: Pursuant to the Fed. Cir. R. 31 practice note, the due date for all appellants' opening briefs is recalculated from the date of docketing of the later consolidated appeal (2016-2698, 9/23/16). Appellants' opening briefs are due 11/22/16. [368974] [AT] [Entered: 09/23/2016 03:49 PM] (0) |
| Sep 22, 2016 | 33 | Note to file: LEAD APPEAL 2016-2610 is consolidated with appeal 2016-2683. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [368593] [AT] [Entered: 09/22/2016 12:29 PM] (0) |
| Sep 22, 2016 | 34 | Official caption revised to reflect the consolidation of the appeal filed by defendants Mylan Pharmaceuticals Inc., Mylan Inc., docketed 9/22/16, as no. 2016-2683, and to add the other 14 consolidated district court case nos. in the nature of proceedings. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [368596] [AT] [Entered: 09/22/2016 12:36 PM] (0) |
| Sep 22, 2016 | 35 | Clerk's Note to the File: Pursuant to the Fed. Cir. R. 31 practice note, the due date for all appellants' opening briefs is recalculated from the date of docketing of the later consolidated appeal (2016-2683, 9/22/16). Appellants' opening briefs are due 11/21/16. [368601] [AT] [Entered: 09/22/2016 12:42 PM] (0) |
| Sep 22, 2016 | 36 | Note to file: LEAD APPEAL 2016-2610 is consolidated with appeal 2016-2685. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [368664] [AT] [Entered: 09/22/2016 03:56 PM] (0) |
| Sep 22, 2016 | 37 | Official caption revised to reflect the consolidation of the appeal filed by defendants Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited, docketed 9/22/16 as no. 2016-2685. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [368667] [AT] [Entered: 09/22/2016 03:58 PM] (0) |
| Sep 22, 2016 | 38 | Clerk's Note to the File: See the previous note at entry 35. Appellants' opening briefs are due 11/21/16. [368669] [AT] [Entered: 09/22/2016 04:00 PM] (0) |
| Sep 21, 2016 | 27 | NOTICE OF DEFICIENCY: The APPELLEES' attorney entries of appearance for A. GAHTAN, L. MORAN, J. TRAINOR, D. DRIVAS, Document Nos. [13] [15] [14] [12] submitted in appeal no. 16-2610 are incomplete and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. CLERK'S NOTE: In the space "Name of Party", all parties must be individually identified (et al. may not be used). If more space is needed, please attach a continuation page to the form. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [367955] [AT] [Entered: 09/21/2016 08:45 AM] (0) |
| Sep 21, 2016 | 28 | Corrected Entry of appearance for Adam R. Gahtan as principal counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Service: 09/21/2016 by email. [368096] [Adam Gahtan] [Entered: 09/21/2016 12:09 PM] (2) |
| Sep 21, 2016 | 29 | Corrected Entry of appearance for Laura T. Moran as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Service: 09/21/2016 by email. [368097] [Adam Gahtan] [Entered: 09/21/2016 12:12 PM] (2) |
| Sep 21, 2016 | 30 | Corrected Entry of appearance for James Trainor as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Service: 09/21/2016 by email. [368099] [Adam Gahtan] [Entered: 09/21/2016 12:14 PM] (2) |
| Sep 21, 2016 | 31 | Corrected Entry of appearance for Dimitrios T. Drivas as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB BioPharma SPRL and UCB, Inc.. Service: 09/21/2016 by email. [368101] [Adam Gahtan] [Entered: 09/21/2016 12:15 PM] (2) |
| Sep 21, 2016 | 32 | Notice of Rejection to Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd., the following document(s) cannot be filed: [26] attorney entry of appearance for ANDREW E. RUSSELL. Reason(s): The attorney is not a member of the Federal Circuit bar. [Note: This notice is text only. No pdf attachment accompanies this notice]. [368269] [AT] [Entered: 09/21/2016 03:30 PM] (0) |
| Sep 20, 2016 | 9 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Appellants' attorney entry of appearance [RICHARD GRECO] Docket No. [6], ERROR: The wrong pdf document was attached to the Entry of Appearance entry. CORRECTION: Please re-file the corrected Entry of Appearance for attorney RICHARD GRECO. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [367585] [AT] [Entered: 09/20/2016 07:48 AM] (0) |
| Sep 20, 2016 | 10 | Entry of appearance for Richard G. Greco as principal counsel for Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 09/20/2016 by US mail, email. [367698] [Richard Greco] [Entered: 09/20/2016 10:52 AM] (2) |
| Sep 20, 2016 | 12 | Entry of appearance for Adam R. Gahtan as principal counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367887] [Adam Gahtan] [Entered: 09/20/2016 04:41 PM] (2) |
| Sep 20, 2016 | 13 | Entry of appearance for Dimitrios T. Drivas as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367890] [Adam Gahtan] [Entered: 09/20/2016 04:43 PM] (2) |
| Sep 20, 2016 | 14 | Entry of appearance for Laura T. Moran as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367891] [Adam Gahtan] [Entered: 09/20/2016 04:46 PM] (2) |
| Sep 20, 2016 | 15 | Entry of appearance for James Trainor as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367893] [Adam Gahtan] [Entered: 09/20/2016 04:48 PM] (2) |
| Sep 20, 2016 | 16 | Entry of appearance for Jeffrey B. Elikan as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367895] [Adam Gahtan] [Entered: 09/20/2016 04:54 PM] (2) |
| Sep 20, 2016 | 17 | Entry of appearance for Alexa R. Hansen as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367897] [Adam Gahtan] [Entered: 09/20/2016 04:56 PM] (2) |
| Sep 20, 2016 | 18 | Entry of appearance for George F. Pappas as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367898] [Adam Gahtan] [Entered: 09/20/2016 04:59 PM] (2) |
| Sep 20, 2016 | 19 | Entry of appearance for Jack B. Blumenfeld as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367899] [Adam Gahtan] [Entered: 09/20/2016 05:00 PM] (2) |
| Sep 20, 2016 | 20 | Entry of appearance for Megan E. Dellinger as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367900] [Adam Gahtan] [Entered: 09/20/2016 05:01 PM] (2) |
| Sep 20, 2016 | 21 | Entry of appearance for Maryellen Noreika as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367901] [Adam Gahtan] [Entered: 09/20/2016 05:02 PM] (2) |
| Sep 20, 2016 | 22 | Entry of appearance for Priscilla G. Dodson as of counsel for Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367902] [Adam Gahtan] [Entered: 09/20/2016 05:07 PM] (2) |
| Sep 20, 2016 | 23 | Certificate of Interest for the Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367904] [Adam Gahtan] [Entered: 09/20/2016 05:15 PM] (5) |
| Sep 20, 2016 | 24 | Docketing Statement for the Appellees Harris FRC Corporation, Research Corporation Technologies, Inc., UCB Biopharma SPRL and UCB, Inc.. Service: 09/20/2016 by email. [367905] [Adam Gahtan] [Entered: 09/20/2016 05:17 PM] (4) |
| Sep 20, 2016 | 25 | Entry of appearance for John W. Shaw as of counsel for Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 09/20/2016 by email. [367914] [John Shaw] [Entered: 09/20/2016 07:26 PM] (1) |
| Sep 20, 2016 | 26 | Entry of appearance for Andrew E. Russell as of counsel for Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 09/20/2016 by email. [367915] This document has been rejected for filing. See Doc. No. [32] [John Shaw] [Entered: 09/20/2016 07:27 PM] (0) |
| Sep 19, 2016 | 5 | Notice of Deficiency to Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd., the following document(s) cannot be filed: [3] certificate of interest, [4] docketing statement, [2] attorney entry of appearance [R. GRECO]. Reason(s): see attached notice. Corrected filings should be submitted promptly. [367203] [AT] [Entered: 09/19/2016 07:30 AM] (1) |
| Sep 19, 2016 | 6 | Entry of appearance for Richard G. Greco as principal counsel for Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 09/19/2016 by US mail, email. [367325] [Richard Greco] [Entered: 09/19/2016 11:31 AM] (3) |
| Sep 19, 2016 | 7 | Certificate of Interest for the Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 09/19/2016 by US mail, email. [367329] [Richard Greco] [Entered: 09/19/2016 11:35 AM] (2) |
| Sep 19, 2016 | 8 | Docketing Statement for the Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 09/19/2016 by US mail, email. [367330] [Richard Greco] [Entered: 09/19/2016 11:37 AM] (3) |
| Sep 19, 2016 | 11 | Paper copies of the docketing statement [4], certificate of interest [3], attorney entry of appearance [2] received from Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd. [CLERK'S NOTE: paper copies of these filings are not permitted by the Rules. These filings have already been entered electronically in the ECF system. The paper copies are discarded.] [367761] [AT] [Entered: 09/20/2016 01:08 PM] (0) |
| Sep 16, 2016 | 2 | Entry of appearance for Richard G. Greco as principal counsel for Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 09/16/2016 by US mail. [367034] [Richard Greco] [Entered: 09/16/2016 02:56 PM] (0) |
| Sep 16, 2016 | 3 | Certificate of Interest for the Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 09/16/2016 by US mail. [367055] This document has been rejected for filing. See Doc. No. [5] [Richard Greco] [Entered: 09/16/2016 03:55 PM] (0) |
| Sep 16, 2016 | 4 | Docketing Statement for the Appellants Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.. Service: 09/16/2016 by US mail. [367058] This document has been rejected for filing. See Doc. No. [5] [Richard Greco] [Entered: 09/16/2016 03:59 PM] (0) |
| Sep 6, 2016 | 1 | Appeal docketed. Received: 09/06/2016. [364351]Entry of Appearance due 09/20/2016. Certificate of Interest due 09/20/2016. Docketing Statement due 09/20/2016. Appellants' brief is due 11/07/2016. [AT] [Entered: 09/06/2016 01:23 PM] (189) |
